Andreas Wollenberg
Department of Dermatology and Allergy, Ludwig-Maximilian University Munich, Germany
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Andreas Wollenberg as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 05:24 UTC. Open this list on ClinicalTrials.gov
- Ph3NCT03131648 · Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 1 (ECZema TRAlokinumab Trial no. 1)LEO Pharma · completed · Atopic Dermatitis · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 05:24 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-12 05:24 UTC. The ranking covers the 200 most relevant of 62 PubMed records, and a shared surname and initials can bring in a namesake. All 62 on PubMed
- Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis.N Engl J Med · 20161,639 citationsRCR 66.2
- Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2).Br J Dermatol · 2021513 citationsRCR 38.5
- Anti-Interleukin-31 Receptor A Antibody for Atopic Dermatitis.N Engl J Med · 2017421 citationsRCR 17.8
- 418 citationsRCR 23.4
- Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb.J Allergy Clin Immunol · 2019314 citationsRCR 15.4
- Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial.J Am Acad Dermatol · 2020309 citationsRCR 20.3
- Safety and efficacy of 1 year of tacrolimus ointment monotherapy in adults with atopic dermatitis. The European Tacrolimus Ointment Study Group.Arch Dermatol · 2000287 citationsRCR 9.4
- 237 citationsRCR 23.1
- Trial of Nemolizumab in Moderate-to-Severe Prurigo Nodularis.N Engl J Med · 2020225 citationsRCR 12.7
- Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus.J Allergy Clin Immunol · 2020211 citationsRCR 12.9